Nasdaq · Healthcare
PTC THERAPEUTICS, INC. (PTCT)
As-reported financials and recent SEC filings for PTC THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.73B
Net income
$682.6M
Net margin
39.4%
Diluted EPS
$7.78
ROE
-332.5%
P/E (TTM)
10.9×
Market cap
$7.00B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M |
| Gross profit | — | — | — | — | — |
| Operating income | $866.9M | $-302.6M | $-439.5M | $-447.4M | $-374.4M |
| Net income | $682.6M | $-363.3M | $-626.6M | $-559.0M | $-523.9M |
| Diluted EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →42026-06-26
View on EDGAR →1442026-06-25
View on EDGAR →1442026-06-24
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →Go deeper on PTCT
Search PTC THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.